1. Efficacy and Safety of a Proposed Ranibizumab Biosimilar Product vs a Reference Ranibizumab Product for Patients With Neovascular Age-Related Macular Degeneration
2. Guidelines on similar biologics: regulatory requirements for marketing authorization in India; August 15, 2016.
3. Scientific Considerations in Demonstrating Biosimilarity to a Reference Product. Guidance for Industry. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER); April, 2015.
4. RanizuRel (ranibizumab) Clinical Study Report (Jan 2020). Reliance Life Sciences. Version 2.0.; January, 2020.